Exelixis Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Exelixis Inc 's ROA in the second quarter of 2026?
Exelixis Inc achieved a return on average assets (ROA) of 70.43 % in its second quarter of 2026, this is above EXEL's average return on assets of 6.37%.
Exelixis Inc s assets during the 12 months ending in the second quarter of 2026 are valued at $2 billion

Despite the company's net income deteriorating, Exelixis Inc was able to improve its ROA compared to the first quarter of 2026.

However, within the Healthcare sector 13 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jul 03 2026 quarter, so far to 53, from total ROA ranking in the first quarter of 2026 at 73.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jul 03 2026) II. Quarter	(Apr 03 2026) I. Quarter	(Jan 02 2026) IV. Quarter	(Oct 03 2025) III. Quarter	(Jul 04 2025) II. Quarter
Y / Y Total Assets Change	-6.4 %	-8.59 %	12.47 %	8.42 %	10.96 %
Y / Y Net Income Change	14.32 %	30.89 %	53.16 %	63.53 %	-19.98 %
Net Income (TTM) in million	1,896	1,837	1,724	1,551	1,378
Return On Assets (TTM)	70.43 %	67.15 %	61.66 %	57.09 %	51.76 %
EXEL's Total Ranking	# 53	# 73	# 67	# 78	# 84
Total Assets (TTM) in million	2,507	2,594	2,844	2,824	2,678
Seq. Total Assets Change	-3.35 %	-8.82 %	0.74 %	5.43 %	-5.61 %
Seq. Net Income Change	-0.72 %	-3.83 %	11.49 %	7.4 %	13.68 %

EXEL's 5 Years Annual ROA >> Back to EXEL Management Effectiveness >> Compare EXEL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 4
Sector	# 14
Overall	# 47

Return On Assets Statistics
High	Average	Low
70.51 %	6.37 %	-65.11 %
(Jul 03 2026)		(Jan 02 2015)

Financial Statements
Exelixis Inc 's Assets	$ 2,507 million	EXEL's Balance sheet
Exelixis Inc 's Income	$ 475 million	Quarterly EXEL's Income Statement
EXEL's Income by Division		See EXEL's Income by Division

Annual Return On Assets	(Jan 02 2026) FY 2025	(Jan 03 2025) FY 2024	(Dec 29 2023) FY 2023	(Dec 30 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	36.34 %	-2.13 %	-9.1 %	13.41 %	26.42 %
Total Assets in million	3,448	2,529	2,584	2,843	2,507
Y / Y Net Income Change	43.3 %	158.53 %	11.68 %	-20.67 %	369.86 %
Net Income in million	1,724	1,203	465	417	525
Annual Return On Assets	49.99 %	47.57 %	18.01 %	14.66 %	20.95 %

EXEL's 5 Years Annual ROA >> Back to EXEL Management Effectiveness >> Compare EXEL ROA to its Competitors

Comment on EXEL's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 49.99 % compared to prior year, due to annual net income growth of 43.3 % to $1,723.78 million, while value of Exelixis Inc 's overall assets grew just by 36.34 % to $3,448.03 million, compared to $3,448.03 a year before.

More Return On Assets Ratios
EXEL's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
EXEL's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for EXEL's Competitors
Subscribers only: Roa for Exelixis Inc 's Suppliers
Subscribers only: Return On Assets for EXEL's Customers

You may also want to know
EXEL's Roi	EXEL's Inventory Turnover Ratio	EXEL's Growth Rates	EXEL's Dividend Comparisons
	EXEL's Profitability Ratios	EXEL's Asset Turnover Ratio	EXEL's Dividend Growth
EXEL's Roe	EXEL's Valuation Ratios	EXEL's Financial Strength Ratios	EXEL's Dividend Payout Ratio

Companies with similar Return On Assets at Jul 03 2026, within Healthcare Sector	ROA
Kyntra Bio Inc	156.80 %
Vor Biopharma Inc	154.23 %
Glucotrack Inc	151.40 %
Capforce Inc	141.40 %
Protagenic Therapeutics Inc new	137.58 %
Elutia Inc	108.72 %
Silexion Therapeutics Corp	99.09 %
Arbutus Biopharma Corp	96.04 %
Pulmatrix Inc	94.81 %
Quince Therapeutics Inc	88.46 %
Interpace Biosciences Inc	85.91 %
Oncotelic Therapeutics Inc	81.75 %
Rigel Pharmaceuticals Inc	72.27 %
Actinium Pharmaceuticals Inc	71.73 %
Sanuwave Health Inc	71.60 %
Exelixis Inc	70.51 %
Rallybio Corporation	64.51 %
Oramed Pharmaceuticals Inc	64.18 %
Fortress Biotech Inc	60.88 %
Atlantic Coastal Acquisition Corp Ii	54.09 %
Lensar Inc	47.48 %
Elite Pharmaceuticals Inc	46.11 %
Omeros Corporation	46.05 %
Q32 Bio Inc	45.18 %
Aurinia Pharmaceuticals Inc	44.95 %
Agenus Inc	44.86 %
Earth Science Tech Inc	44.02 %
Liquidia Corporation	36.30 %
Ironwood Pharmaceuticals inc	34.34 %
Idexx Laboratories Inc	33.61 %

Date modified: 2026-09-13T23:29:29+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.